Concierge and longevity practices are increasingly asked about regenerative protocols that pair peptides, often used as adjuvants to therapy, with exosome-based products. The two categories sit in very different regulatory places, and understanding how they fit together (and where the legal lines fall) is essential before a clinic builds a service line around them. This article covers the science, the sourcing pathways, and the compliance guardrails practitioners should have in place.
Why Concierge and Longevity Clinics Offer Peptides and Exosomes
The concierge model rewards differentiated, membership-based services that patients cannot easily find elsewhere. Regenerative and longevity-focused offerings fit that positioning well. Peptides have a long clinical research history across metabolic, recovery, and tissue-repair pathways, while exosomes represent an active frontier in cell-to-cell signaling research. Clinics that combine them are usually working to address both a signaling input and targeted physiological pathways within a single, structured protocol.
Key Distinction
Peptides used in clinical practice are typically prescribed and compounded through licensed pharmacies. Exosome products, by contrast, are not FDA-approved for treating any disease and are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research. These two categories should never be marketed as interchangeable.
Peptides: What They Are and How Clinics Source Them Compliantly
Peptides are short chains of amino acids that act as signaling molecules in the body. In a clinical setting, specific peptides are prescribed by a licensed provider and prepared by a compounding pharmacy. The sourcing pathway determines what a clinic can legally stock and how it can be used.
503A vs 503B Sourcing for Peptides
The distinction between 503A and 503B pharmacies shapes nearly every peptide sourcing decision a clinic makes.
- 503A pharmacies prepare patient-specific compounds under state board oversight, tied to an individual prescription.
- 503B outsourcing facilities are FDA-registered, follow cGMP, and can supply office-use inventory in bulk.
- Only compounds using bulk substances that appear on the applicable FDA lists (or that meet the relevant criteria) can be lawfully prepared.
- Lot numbers and sterility documentation should be available for every order, with the certificate of analysis available on request for each lot.
Exosomes: Signaling Vesicles for Topical Aesthetic Use and Research
Exosomes are nano-sized extracellular vesicles (roughly 40 to 160 nm, about 100 nm on average) that carry proteins, lipids, and nucleic acids between cells. Research interest centers on their role in intercellular communication: a 2025 review of 90 human clinical trials found promising safety and efficacy signals and pointed to larger randomized trials and standardized isolation as the field’s next step. It is important to state clearly what regulatory status they hold.
Regulatory Status
As of 2026, there are no FDA-approved exosome products for the treatment of any disease or condition, and the FDA has issued multiple safety communications on this point. ExaVeyra supplies exosome material for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, with full characterization and documentation.
Where Exosomes Can Be Used Today
The absence of an FDA approval does not mean exosomes have no legitimate place in a practice. It means the permitted contexts are specific and must be described accurately. Within those boundaries there is meaningful, growing activity.
- Topical aesthetic applications on intact skin, where the product stays above the dermis and no claim is made to treat, cure, or prevent any disease.
- Cosmetic formulations marketed for appearance and skin quality rather than a medical outcome, kept within cosmetic labeling rules.
- Laboratory research, and clinical research conducted under an IND, with full characterization data.
- Registered clinical trials across several research areas, from dermatology to musculoskeletal research, conducted under an FDA investigational new drug application (IND).
The Line That Matters
The determining factor is the claim and the route of administration. A topical product on intact skin marketed for appearance sits in a very different regulatory place than an injected product marketed to treat a condition. Investigational indications belong in registered trials, not routine practice, until data and approvals support them.
How Peptide Prescriptions and Exosome Supply Fit Together
In research and clinical-investigation contexts, combination protocols are typically organized around the timing, sequencing, and characterization of each input. A structured protocol documents the source, concentration, and handling of every component.
| Protocol Element | Peptide Component | Exosome Component |
|---|---|---|
| Regulatory basis | Prescription plus 503A/503B compounding | Topical aesthetic use and research; not for treatment |
| Sourcing documentation | COA, lot number, pharmacy license | COA, vesicle count, sterility panel |
| Handling | Reconstitution per pharmacy guidance | Cold-chain, characterization on receipt |
| Marketing claims | Within the approved prescribing context | No disease-treatment claims permitted |
What Practitioners Should Verify Before Adopting a Protocol
- The prescribing provider holds appropriate licensure and follows applicable state and federal rules.
- Peptide compounds come from a pharmacy whose 503A or 503B status matches the intended use.
- Exosome material arrives with characterization data and the manufacturer’s labeling.
- Material supplied for research is used only in the laboratory or under an IND, and exosome material used in practice follows the manufacturer’s topical aesthetic labeling.
- Supply chain partners provide full traceability, with a certificate of analysis available on request for each lot.
The clinics that build durable regenerative service lines are the ones that treat compliance as a feature, not an obstacle.
The 2026 Regulatory Landscape
The compounding landscape continues to evolve. Providers should track FDA guidance on bulk drug substances, state board positions on peptide compounding, and the agency’s ongoing communications about unapproved cell- and tissue-based products. A protocol that was compliant last year may need revision as lists and guidance change.
Building a Compliant Supply Chain
A defensible regenerative program rests on documentation. Clinics should work with sourcing partners who verify licensure, provide a certificate of analysis on request for each lot, maintain cold-chain integrity, and label every material with its intended use. ExaVeyra Sciences was built around this chemist-reviewed, documentation-first model.
Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. Exosome material referenced is supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and is not FDA-approved to diagnose, treat, cure, or prevent any disease. Peptide protocols require a valid prescription and appropriate licensure. Practitioners are responsible for compliance with all applicable state and federal regulations.
References
- 1.U.S. Food & Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes.
- 2.U.S. Food & Drug Administration. Compounding and the FDA: Questions and Answers (Sections 503A and 503B). fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers.
- 3.Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
- 4.Mohan S, Khamjan NA, Abdelwahab SI, et al. Clinical frontiers of exosome research: a comprehensive analysis of human trials in diagnostics, therapeutics, and regenerative medicine. J Pharmacol Pharmacother. 2025;17(2):174-190. doi:10.1177/0976500X251361201.
- 5.U.S. Food & Drug Administration. Public Safety Notification on Exosome Products. fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products.